Going Big on Data and Digital in the Health & Life Science Sector

While it’s increasingly clear that disruptive technologies from Silicon Valley will radically change the way that we make and test medicines, biopharma and healthcare need to level up in digital. Novartis made “Going Big on Data and Digital” one of the five top priorities of the company. But what does this mean in reality? The presenters will share with you some first insights into the Novartis digital strategy, including five disruptive scenarios that the company is exploring and look forward to a vivid discussion of what this could imply for the IP and Legal field. The idea is to learn from each other and to initiate fruitful discussions in an increasingly important area of research and innovation.

Programme, about the speakers and registration